Sacituzumab tirumotecan is a new drug that belongs to a group of antibiotic conjugates targeting the TROP2 protein found on the surface of lung cancer cells.[1] In a phase 3 clinical trial, it was tested in 376 patients with advanced lung cancer (NSCLC) with an EGFR gene mutation who no longer responded to standard EGFR-inhibitor-based drugs.[1] Patients were randomly divided into two groups - one receiving sacituzumab tirumotecan and the other standard chemotherapy with platinum and pemetrexed.[1] The median time without disease progression was 8.3 months in the new drug group versus 4.3 months in the chemotherapy group.[1] Overall survival was also significantly better - at 18 months, 65.8% of patients treated with the new drug survived compared to 48% of patients treated with chemotherapy.[1] The new drug reduced the risk of progression or death by 51%.[4] Side effects were less serious—serious adverse events occurred in 9% of patients treated with sacituzumab tirumotecan versus 17.6% in the chemotherapy group.[3]